GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Champions Oncology Inc (NAS:CSBR) » Definitions » YoY EPS Growth

CSBR (Champions Oncology) YoY EPS Growth : 147.37% (As of Jul. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Champions Oncology YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Champions Oncology's YoY EPS Growth for the quarter that ended in Jul. 2024 was 147.37%.

Champions Oncology's Earnings per Share (Diluted) for the three months ended in Jul. 2024 was $0.09.


Champions Oncology YoY EPS Growth Historical Data

The historical data trend for Champions Oncology's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Champions Oncology YoY EPS Growth Chart

Champions Oncology Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,900.00 111.11 100.00 -1,075.00 -38.46

Champions Oncology Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -850.00 -14,900.00 -5.56 94.74 147.37

Champions Oncology YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Champions Oncology's YoY EPS Growth for the fiscal year that ended in Apr. 2024 is calculated as:

YoY EPS Growth (A: Apr. 2024 )
=(Earnings per Share (Diluted) (A: Apr. 2024 )-Earnings per Share (Diluted) (A: Apr. 2023 ))/ | Earnings per Share (Diluted) (A: Apr. 2023 ) |
=(-0.54--0.39)/ | -0.39 |
=-38.46 %

Champions Oncology's YoY EPS Growth for the quarter that ended in Jul. 2024 is calculated as:

YoY EPS Growth (Q: Jul. 2024 )
=(Earnings per Share (Diluted) (Q: Jul. 2024 )-Earnings per Share (Diluted) (Q: Jul. 2023 )) / | Earnings per Share (Diluted) (Q: Jul. 2023 )) |
=(0.09--0.19)/ | -0.19 |
=147.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Champions Oncology YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Champions Oncology's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Champions Oncology Business Description

Traded in Other Exchanges
Address
One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
Executives
Daniel Newman Mendelson director COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR, SUITE 900, BETHESDA MD 20817
Ronnie Morris director, officer: President 855 N. WOLFE STREET, SUITE 619, BALTIMORE MD 21205
Philip P. Breitfeld director ONE UNIVERSITY PLAZA, SUITE 307, HACKENSACK NJ 07601
New Enterprise Associates 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Neeraj Agrawal 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Roger H Lee 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Michael Maurice Brown 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Battery Management Corp. 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
R David Tabors 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Jesse Feldman 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Joel Ackerman director, officer: Chief Executive Officer COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817
Patrick J Kerins 10 percent owner
Ryan D Drant 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Harry R Weller 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815